Request Demo

Last update 30 Apr 2026

Omadacycline Tosylate

Last update 30 Apr 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Amadacycline, Neopentyl aminomethylminocycline, Omadacycline

+ [13]

Target

30S subunit

Action

inhibitors

Mechanism

30S subunit inhibitors(30S ribosomal subunit inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesSkin and Musculoskeletal Diseases

Active Indication

Community-acquired bacterial pneumoniaSkin and skin structure infectionsArthropathy associated with infection+ [3]

Inactive Indication

Acute pyelonephritisCellulitisComplicated skin and skin structure infection+ [8]

Originator Organization

Paratek Pharmaceuticals, Inc.

Active Organization

Paratek Pharmaceuticals, Inc.

Zai Lab (Shanghai) Co., Ltd.

Zhejiang Hisun Pharmaceutical Co., Ltd.

+ [1]

Inactive Organization

Hangzhou Ausia Biological Technology Co. Ltd.

Novartis Pharmaceuticals Corp.

License Organization

Paratek Pharmaceuticals, Inc.

Merck & Co., Inc.

Novartis AG

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (02 Oct 2018),

Community-acquired bacterial pneumoniaSkin and skin structure infections

RegulationOrphan Drug (United States), Orphan Drug (European Union), Fast Track (United States)

Structure/Sequence

Molecular FormulaC36H48N4O10S

InChIKeySETFNHZTVGTBHC-XGLFQKEBSA-N

CAS Registry1075240-43-5

Clinical Trials associated with Omadacycline Tosylate

NCT06462326

/ CompletedPhase 1

A Phase 1, Randomized, Double-Blind Study to Compare the Effect of Omadacycline PO Versus Moxifloxacin PO on the Gut Microbiota in Healthy Adult Volunteers

This is a randomized (1:1), double-blind, double-dummy, phase I study to compare the effects of Omadacycline versus Moxifloxacin on gut microbiota and the resistomes in healthy adult volunteers.The study consists of 3 phases: Screening, double-blind treatment, and follow-up. Healthy volunteers aged 18-40 years, who meet entry criteria, are randomly assigned to a treatment group using an Interactive Voice Response System/Interactive Web Response System (IxRS) and receive the first dose of the study drug.

Start Date16 Apr 2024

Sponsor / Collaborator

Zai Lab (Hong Kong) Ltd.

NCT06162286

/ RecruitingPhase 3

A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-acquired Bacterial Pneumonia (CABP)

The primary objective of the study is to show that in Chinese adults with CABP, a course of IV/PO treatment with omadacycline has similar clinical efficacy as the with the comparator antibiotic, IV/PO moxifloxacin. The study is designed as a bridging study, to confirm the results of the pivotal global CABP trial in an ethnically different population of Chinese.

Start Date17 Nov 2023

Sponsor / Collaborator

Zai Lab (Hong Kong) Ltd.

NCT05753215

/ Active, not recruitingPhase 2IIT

Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: An Open-Label, Non- Inferiority, Randomized, Controlled Trial

The study design is a randomized, open-label, clinical trial of omadacycline vs Standard of Care (SOC) antibiotics for bone and join infection (BJI) treatment. Study participants will have their BJI regimen chosen by their treating physicians, (typically Infectious Diseases for hardware and prosthetic joint infections, or multidisciplinary Limb Salvage team for diabetic foot infections) prior to enrollment. Then participants will be randomized to an omadacycline-containing regimen versus the a priori chosen SOC regimen. Participants must require between 4 and 12 weeks of therapy for their BJI. The exact duration of therapy will be decided by the participants' treating physician. At 12 weeks, if the treating physician wishes to extend therapy, participants receiving omadacycline will be transitioned to other SOC antibiotics.
Once enrolled, participants will be followed via in-person clinic visits at the following intervals: weeks 0, 2, 4, 8, and 12. A final in-person visit will occur 2 weeks post-treatment completion. A phone survey will occur 3 months post-treatment completion. Participants in the SOC group will follow the same schedule.
Oral once-daily dosing options for S. aureus and Coagulase negative Staphylococcus are essentially non-existent. Thus, omadacycline possesses a novel and advantageous option for BJI treatment. Its convenient dosing regimen will almost certainly be associated with improved adherence, and higher adherence may, in turn, improve clinical outcome. Investigators hypothesize that omadacycline will be a well-tolerated and efficacious oral antibiotic for BJIs and will be associated with improved adherence compared with standard of care oral antibiotics. Investigators believe omadacycline addresses the unmet need for an oral antibiotic that is well-tolerated and efficacious for use as a prolonged therapy for BJIs. To this aim, investigators will perform a randomized, open-label clinical trial of omadacycline to SOC antibiotics for BJIs.

Start Date09 May 2023

Sponsor / Collaborator

The Lundquist Institute

[+2]

100 Clinical Results associated with Omadacycline Tosylate

100 Translational Medicine associated with Omadacycline Tosylate

100 Patents (Medical) associated with Omadacycline Tosylate

377

Literatures (Medical) associated with Omadacycline Tosylate

01 Mar 2026·Clinical Pharmacology in Drug Development

Comparison of Efficacy and Safety Profiles Between Omadacycline and Moxifloxacin in Elderly Patients with Community‐Acquired Pneumonia: A Randomized, Controlled Trial

Article

Author: Liu, Yancun ; Zhou, Zikang ; Wang, Xiaorong ; Yu, Muming ; Chai, Yanfen ; Wu, Sitong

Abstract:

Omadacycline is a novel aminomethylcycline antibiotic that shows non‐inferior efficacy to moxifloxacin in adults with community‐acquired pneumonia (CAP), but lacking clinical evidence in elderly patients with CAP. This randomized, controlled study aimed to investigate the efficacy and safety of omadacycline in elderly patients with CAP. Eligible elderly patients with CAP were randomized at a 1:1 ratio to the omadacycline group (n = 48) and moxifloxacin group (n = 49) to receive the corresponding agent. The primary endpoint was clinical response. The most common pathogens in the omadacycline and moxifloxacin groups were viridans streptococci (16.7%, 16.3%), Klebsiella pneumoniae (14.6%, 14.3%), and Neisseria sicca (14.6%, 14.3%). Clinical response rate was greater in the omadacycline group compared to the moxifloxacin group (54.2% vs 26.5%, P = .032). The omadacycline group showed higher significant improvement rate (41.7% vs 16.3%, P = .02), but similar complete recovery (12.5% vs 10.2%, P = .737), effective improvement (37.5% vs 59.2%, P = .125), and ineffectiveness (8.3% vs 14.3%, P = .384) rates compared to the moxifloxacin group. Results of C‐reactive protein, procalcitonin, and interleukin‐6 at baseline and after treatment, as well as their changes did not vary between the omadacycline and moxifloxacin groups (all P > .05). No difference was observed in liver, kidney, and coagulation function parameters between the two groups (all P > .05). Omadacycline indicates greater treatment efficacy and comparable safety profiles versus moxifloxacin in elderly patients with CAP.

02 Feb 2026·Open Forum Infectious Diseases

Recovery and Stability of Omadacycline 150-mg Crushed Tablets Dispersed in Food or Water and Administered via Nasogastric Tube

Article

Author: Garey, Kevin W ; Huynh-Phan, Ricky ; Hu, Chenlin ; Eubank, Taryn A ; Rodriguez Robles, Kevin M

Abstract:

Background:

Omadacycline, an aminomethylcycline tetracycline available orally and intravenously, is approved for the treatment of patients with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, some of whom have difficulty swallowing tablets. The objective of this study was to assess the stability and recovery of crushed omadacycline 150-mg tablets.

Methods:

The recovery and stability of crushed omadacycline 150-mg tablets was assessed using 3 crushing methods (pill crusher, mortar/pestle, and sandwich bag method) and 3 dispersal products (water, vanilla syrup, or applesauce) over 24 hours at room temperature and administered via nasogastric tube. Omadacycline and its epimer (OMC-4-epimer) concentrations were assessed via liquid chromatography tandem mass spectrometry.

Results:

There was no significant difference in recovery of omadacycline or OMC-4-epimer proportion based on crushing technique. There were significantly higher proportions of OMC-4-epimer in applesauce experiments than in water or vanilla syrup experiments, regardless of crushing methods. All experiments had significantly less recovery of omadacycline and increased proportions of OMC-4-epimer at 24 hours compared with earlier time points. There was no significant difference in recovery of omadacycline or OMC-4-epimer proportion using either type of nasogastric tube with omadacycline recovery above 91%.

Conclusions:

The optimal method for recovery and stability of crushed omadacycline was to rinse the crushing device thoroughly into the collection container and disperse it into water, with consumption immediately or after no more than 4 hours. Vanilla syrup may be used as an alternative dispersal vehicle to be consumed immediately if used.

19 Jan 2026·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database

Article

Author: Qu, Jian ; Wang, Yi-Ming ; Zhao, Ye-Lei ; Qu, Qiang ; Zhang, Yan-Tao

Abstract:

Objective:

Omadacycline, a novel aminomethylcycline antibiotic for community-acquired bacterial infections, lacks comprehensive real-world safety data. We evaluated its adverse drug reactions (ADRs) using the FDA Adverse Event Reporting System (FAERS).

Methods:

A comprehensive analysis of post-marketing ADR reports submitted to FAERS between the first quarter of 2020 and the fourth quarter of 2024 was conducted. Disproportionality signals were assessed via four methods: reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network and multi-item gamma Poisson shrinker.

Results and conclusion:

Among 4541 omadacycline-related reports, 577 distinct ADRs were identified. The most frequently reported ADRs were nausea (221 cases, 14.1%), vomiting (129), diarrhoea (93), dyspnoea (56) and rash (52). The strongest safety signals (ROR) included tooth discolouration (ROR = 184.33, 95% CI = 96.79–351.06), tongue discolouration (159.88, 101.76–251.25) and Mycobacterium avium complex infection (73.30, 40.15–133.78). Hepatic events (e.g. elevated transaminases) and mortality (49 cases) also demonstrated significant signals. Omadacycline is associated with gastrointestinal disturbances, dental discolouration and respiratory complications. Vigilance for hepatic injury and mortality is warranted, especially in elderly comorbid patients. Ongoing pharmacovigilance integrating real-world evidence is essential.

106

News (Medical) associated with Omadacycline Tosylate

16 Apr 2026

·www.biospace.com

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026

Highlights include pooled safety findings from Paratek’s Phase 3 studies in community acquired pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI), as well as additional clinical and non-clinical data from Company- and investigator-sponsored studies KING OF PRUSSIA, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on high-need, targeted therapeutic areas, today announced that new data from scientific and investigator-initiated studies of NUZYRA ® (omadacycline) will be presented at ESCMID Global 2026, the annual Congress of the European Society of Clinical Microbiology and Infectious Diseases, taking place in Munich, Germany, April 17-21. “At this month’s ESCMID conference, we will present the most comprehensive safety review to date for NUZYRA in both pneumonia and skin infections, based on data from four Phase 3 trials in more than 1,400 patients,” said Randy Brenner, Chief Development and Regulatory Officer of Paratek. “In addition, we will have a poster of pivotal data from our rabbit study under the Animal Rule product development program, which we expect will help support a future sNDA submission for NUZYRA for the treatment of pulmonary anthrax. We are also pleased to continue to support high-caliber investigator-sponsored research, as will be presented at this week’s meeting.” ESCMID Poster Sessions Poster Title: An Integrated Safety Analysis of Omadacycline in Pivotal Phase 3 Clinical Trials Session: 05e. Safety, hypersensitivity and adverse effects of treatment Presenter: Maria Amodio-Groton, PharmD (Paratek research) Session Date, Time: Sunday, Apr. 19, 12:00 p.m. – 1:30 p.m. CEST (6:00 a.m. – 7:30 a.m. U.S. EDT) Location: Messe München Poster Hall B3 Poster ID: P3082 (The study has been supported in whole or part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under contract number 75A50120C00001.) (The safety analysis integrates data from Paratek’s four Phase 3 studies: two ABSSSI studies (OASIS-1, OASIS-2) and two CABP studies (OPTIC, OPTIC-2). Safety and efficacy data from the OPTIC-2 study were published in December 2025 in eClinicalMedicine , a Lancet Discovery Science journal, .) Poster Title: Omadacycline Demonstrated Efficacy as Therapeutic Treatment against Inhalation Anthrax in a Blinded, Randomized, Pivotal Study in New Zealand White Rabbits Session: 09b. Host-pathogen interaction (incl basic microbiome studies, animal models) Presenter: Alisa Serio, Ph.D. (Paratek research) Session Date, Time: Monday, Apr. 20, 12:00 p.m. – 1:30 p.m. CEST (6:00 a.m. – 7:30 a.m. U.S. EDT) Location: Messe München Poster Hall B3 Poster ID: P3998 (The anthrax-related project has been supported in whole or part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under contract number 75A50120C00001.) Poster Title: Efficacy and Safety of Omadacycline Oral Step-Down Therapy Following Bloodstream Infection: A Real-World Descriptive Study Session: 05c. New or repurposed antibacterial agents: Clinical studies and randomised trials Presenter: Sean Van Helden, PharmD (Investigator-initiated research) Session Date, Time: Sunday, Apr. 19, 12:00 p.m. – 1:30 p.m. CEST (6:00 a.m. – 7:30 a.m. U.S. EDT) Location: Messe München Poster Hall B3 Poster ID P2881 About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a specialty pharmaceutical company with a portfolio of differentiated medicines serving patients across multiple therapeutic areas. The company integrates and advances commercial-stage assets through disciplined commercial execution, lifecycle management, and clinical development initiatives designed to expand and strengthen its portfolio. Paratek's products include NUZYRA ® (omadacycline), XHANCE ® (fluticasone propionate), and TYMLOS ® (abaloparatide). Paratek is privately held by B-FLEXION Life Sciences. In December 2019, BARDA awarded Paratek a PBS contract (75A50120C00001) that is now valued at up to approximately $304 million. In addition to supporting the development of NUZYRA for both the treatment and prophylaxis of pulmonary anthrax, this contract supports the U.S. onshoring of NUZYRA and manufacturing security requirements; FDA post-marketing requirements associated with the initial NUZYRA approval; and the procurement of up to 10,000 treatment courses of NUZYRA for the treatment of anthrax. For more information, visit or follow us on LinkedIn and X . About NUZYRA NUZYRA (omadacycline) is an antibiotic with both once-daily oral and intravenous (IV) formulations indicated for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible microorganisms. A next-generation tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypical, and other drug-resistant strains. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline class antibacterial drugs, or to any of the excipients. WARNINGS AND PRECAUTIONS Mortality imbalance was observed in the CABP clinical trial, with eight deaths (2%) occurring in patients treated with NUZYRA compared to four deaths (1%) in patients treated with moxifloxacin. The cause of the mortality imbalance has not been established. All deaths, in both treatment arms, occurred in patients >65 years of age; most patients had multiple comorbidities. The causes of death varied and included worsening and/or complications of infection and underlying conditions. Closely monitor clinical response to therapy in CABP patients, particularly in those at higher risk for mortality. The use of NUZYRA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. The use of NUZYRA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. Hypersensitivity reactions have been reported with NUZYRA. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline class antibacterial drugs. NUZYRA is structurally similar to other tetracycline class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline class antibacterial drugs. Discontinue NUZYRA if an allergic reaction occurs. Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. NUZYRA is structurally similar to tetracycline class antibacterial drugs and may have similar adverse reactions. Adverse reactions, including photosensitivity, fixed drug eruption, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests), have been reported for other tetracycline class antibacterial drugs, and may occur with NUZYRA. Discontinue NUZYRA if any of these adverse reactions are suspected. Prescribing NUZYRA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. ADVERSE REACTIONS The most common adverse reactions (incidence ≥2%) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation. DRUG INTERACTIONS Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA. Absorption of tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations. USE IN SPECIFIC POPULATIONS Lactation: Breastfeeding is not recommended during treatment with NUZYRA. See full prescribing information here . MEDIA CONTACT: Adam Silverstein adam@scientpr.com

18 Mar 2026

·www.biospace.com

Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform

Transaction adds TYMLOS ® to portfolio alongside NUZYRA ® and XHANCE ® and creates a diversified portfolio expected to generate nearly $1 billion in revenue in 2026 KING OF PRUSSIA, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on high-need, targeted therapeutic areas, today announced the completion of its combination with Radius Health, Inc., adding the osteoporosis therapy TYMLOS ® (abaloparatide) to its growing commercial portfolio of differentiated specialty medicines. Paratek is a specialty pharmaceutical platform company with a portfolio of diverse, innovative medicines well positioned for long-term growth. The company integrates and advances assets through disciplined commercial execution, lifecycle management, and clinical development, with a proven track record of integrating and growing pharmaceutical assets across multiple therapeutic areas. The transaction, which closed this week, brings together two complementary organizations backed by B-FLEXION Life Sciences, and further advances Paratek’s growth strategy of building a pharmaceutical platform in high-need, targeted therapeutic areas. The combined company is expected to generate nearly $1 billion in revenue in 2026, reflecting the scale and breadth of Paratek’s platform. “Today marks an important milestone for both Paratek and Radius,” said Evan Loh, M.D., Chief Executive Officer of Paratek. “Radius has built an impressive organization under the leadership of CEO Scott Briggs and its dedicated and talented team, and we look forward to building on that strong foundation together as we enter this next chapter. With our combined expertise in serving specialists and patients with significant, focused medical needs, we are well positioned to expand the impact of our medicines and continue delivering meaningful therapies to the patients and communities who rely on us.” Nithya Desikan, Operating Partner at B-FLEXION Life Sciences and Chair of the Board of Paratek, said: “We couldn’t be more pleased about the combination of these two companies and are committed to investing and building on their remarkable track records. With its scientific and commercial excellence and unwavering commitment to improving the lives of patients, Radius has done outstanding and innovative work establishing TYMLOS as an important therapy for osteoporosis. Paratek has a similarly strong track record of commercial and operational excellence, including successfully integrating targeted pharmaceutical assets. By bringing these organizations together, we are confident that Paratek is poised to accelerate growth for its expanding platform of innovative medicines that address significant patient needs.” With the completion of this transaction, Paratek’s portfolio will span infectious disease, podiatry, otolaryngology, allergy, rheumatology, endocrinology, and gynecology, supported by experienced medical, commercial, and operational teams with deep expertise in serving specialist physicians and patients with significant medical needs. The transaction adds TYMLOS to Paratek’s portfolio alongside NUZYRA ® (omadacycline), a once-daily antibiotic therapy for serious community-acquired infections, including complicated skin infections and pneumonia; and XHANCE ® (fluticasone propionate), a treatment for chronic rhinosinusitis with or without nasal polyps. “We are thrilled to announce the successful closing of this combination, which represents another significant achievement for the B-FLEXION Life Sciences platform,” said Peter Agnes, Operating Partner at B-FLEXION Life Sciences. “Our strategy has been to build a diversified life sciences platform anchored by high-quality, durable assets with meaningful impact for patients. This combination reflects that long-term commitment. We remain focused on identifying and acquiring additional important products that complement our platform and drive sustainable, long-term value creation. We have immense conviction in the potential and future success of Paratek as it enters this next phase of growth.” B-FLEXION Life Sciences acquired Paratek in 2023 and has since positioned the company as a platform for building a diversified specialty portfolio. The transaction was financed with capital from B-FLEXION Life Sciences and debt financing from funds managed by Blackstone Credit & Insurance; Sixth Street; Oaktree Capital Management, L.P.; Silver Point Capital; and Pharmakon Advisors, LP, with Wilmington Trust, National Association, serving as administrative agent. Lazard acted as the exclusive financial advisor to B-FLEXION Life Sciences and Paratek Pharmaceuticals, and Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to B-FLEXION Life Sciences and Paratek Pharmaceuticals. About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a specialty pharmaceutical company with a portfolio of differentiated medicines serving patients across multiple therapeutic areas. The company integrates and advances commercial-stage assets through disciplined commercial execution, lifecycle management, and clinical development initiatives designed to expand and strengthen its portfolio. Paratek’s products include NUZYRA ® (omadacycline), XHANCE ® (fluticasone propionate), and TYMLOS ® (abaloparatide). Paratek is privately held by B-FLEXION Life Sciences. For more information, visit or follow us on LinkedIn and X . About B-FLEXION Life Sciences B-FLEXION Life Sciences is an investment manager and part of the wider B-FLEXION group, the private, entrepreneurial investment firm that has offices across Europe and the United States and which seeds, acquires and builds investment partnerships across a number of focused fields. Through B-FLEXION Life Sciences it also makes principal investments in operating businesses across biotech, therapeutics, diagnostics, physician practice management, and more. It is an active owner, applying the experience and skills of its investment and operations team to work closely with management at its portfolio companies with the shared goals of bringing safe and effective treatments to market while also moving towards and through key value inflection points. MEDIA CONTACT: Adam Silverstein adam@scientpr.com

AcquisitionExecutive Change

26 Feb 2026

·www.biospace.com

Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

– Total revenues grew 17% y-o-y to $127.6 million for the fourth quarter of 2025 and 15% y-o-y to $460.2 million for the full-year 2025 – Zocilurtatug pelitecan (zoci) on track to become Zai Lab’s first global oncology launch, with three registration-enabling studies across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026 – Advancing a differentiated global pipeline, including ZL-1503 (IL-13/IL-31Rα), ZL-6201 (LRRC15 ADC), ZL-1222 (PD-1/IL-12) and ZL-1311 (MUC17/CD3 TCE) – Key regional programs continue to advance, with KarXT approved in China and commercial launch preparations underway; pivotal data readouts for povetacicept in IgAN and elegrobart in TED expected in 2026 Conference call and webcast today, February 26, 2026, at 8:00 a.m. ET (9:00 p.m. HKT) SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2025, along with recent product highlights and corporate updates. “2025 was a year of disciplined execution across both engines of our business with significant advancement across our global innovation pipeline and steady progress in our commercial business,” said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. “We accelerated multiple global programs, including the rapid progression of zoci into pivotal development, enabled by our integrated U.S./China infrastructure which allows us to operate with speed and capital efficiency. In 2026, our focus is on executing against important catalysts – advancing late-stage immunology and oncology programs while preparing for the next wave of commercial growth. Together, these efforts mark an important step in Zai Lab’s continued evolution into a global biopharma leader.” “KarXT represents a significant new growth driver for Zai Lab, and its recent inclusion in a national expert consensus underscores the growing recognition of its novel mechanism and potential to meaningfully impact patients living with schizophrenia,” said Josh Smiley, President and Chief Operating Officer of Zai Lab. “We are strengthening the VYVGART franchise by expanding hospital coverage and supporting longer treatment persistence. Concurrently, we are preparing for the potential approvals of TIVDAK, which would further strengthen our women’s health franchise, and TTFields in pancreatic cancer. Looking beyond 2026, the combination of new launches, potential label expansions and advancing global programs, positions us for multi-year growth and continued financial improvement.” Fourth Quarter and Full-Year 2025 Financial Results Total revenue was $127.6 million in the fourth quarter of 2025 and $460.2 million for the full-year 2025. Product revenue, net was $127.1 million in the fourth quarter of 2025, compared to $108.5 million for the same period in 2024, representing 17% y-o-y growth and 16% at constant exchange rate (CER); and was $457.2 million in full-year 2025, compared to $397.6 million for the same period in 2024, representing 15% y-o-y growth and 16% y-o-y growth at CER. This increase was primarily due to higher revenue for XACDURO and NUZYRA. – ZEJULA was $56.0 million in the fourth quarter of 2025, an increase of 16% y-o-y from $48.4 million; and was $189.0 million in full-year 2025, compared to $187.1 million for the same period in 2024. ZEJULA continued to be the leading PARP inhibitor in hospital sales for ovarian cancer despite evolving competitive dynamics within the PARPi class in mainland China. – VYVGART and VYVGART Hytrulo were $21.9 million in the fourth quarter of 2025 which includes a $5.6 million rebate for VYVGART related to the National Reimbursement Drug List (NRDL) renewal, compared to $30.0 million for the same period in 2024; and was $94.2 million in full-year 2025, compared to $93.6 million for the same period in 2024. – XACDURO, which was launched in the fourth quarter of 2024, was $10.7 million in the fourth quarter of 2025, an increase of 225% y-o-y from $3.3 million; and was $22.9 million in full-year 2025, an increase of 593% y-o-y from $3.3 million. Growth was driven by strong patient demand and expanding hospital adoption but was partially constrained by supply limitations during the year. – NUZYRA was $16.0 million in the fourth quarter of 2025, an increase of 45% y-o-y from $11.0 million; and was $60.8 million in full-year 2025, an increase of 41% y-o-y from $43.2 million. This growth was supported by increased market coverage and penetration. Research and Development (R&D) expenses were $61.6 million in the fourth quarter of 2025, compared to $52.3 million for the same period in 2024, and $220.9 million for full-year 2025, compared to $234.5 million for the same period in 2024. The fourth-quarter increase resulted from progress in clinical trials. The full year decline was primarily driven by lower personnel compensation due to strategic resource optimization. Selling, General and Administrative (SG&A) expenses were $73.0 million in the fourth quarter of 2025, compared to $82.6 million for the same period in 2024, and $277.6 million for full-year 2025, compared to $298.7 million for the same period in 2024. The decrease was primarily due to a reduction in general and administrative expenses due to strategic resource optimization. Loss from operations was $69.4 million and $229.4 million in the fourth quarter of 2025 and full-year 2025, respectively, and $49.6 million and $148.8 million, respectively, when adjusted to exclude non-cash expenses, including depreciation, amortization, and share-based compensation. Loss from operations was $67.9 million and $282.1 million in the fourth quarter of 2024 and full-year 2024, respectively. A reconciliation of loss from operations (GAAP) to adjusted loss from operations (non-GAAP) is included at the end of this release. Net loss was $50.4 million in the fourth quarter of 2025, or a loss per ordinary share attributable to common stockholders of $0.05 (or loss per American Deposit Share (ADS) of $0.46), compared to a net loss of $81.7 million for the same period in 2024 or a loss per ordinary share of $0.08 (or loss per ADS of $0.80). The net loss was $175.5 million for full-year 2025, or a loss per ordinary share attributable to common stockholders of $0.16 (or loss per ADS of $1.60), compared to a net loss of $257.1 million for full-year 2024, or a loss per ordinary share of $0.26 (or loss per ADS of $2.60). These decreases in net loss were primarily due to product revenue growing faster than net operating expenses and shift from foreign currency losses to foreign currency gains, offset by decreased interest income. Cash and cash equivalents, short-term investments and current restricted cash totaled $789.6 million as of December 31, 2025, compared to $879.7 million as of December 31, 2024. 2026 Strategic Priorities Zai Lab will focus on the following strategic priorities in 2026 to drive near-term performance and long-term global value creation: Advancing Differentiated Global Programs Across Oncology and Immunology Zocilurtatug pelitecan (zoci) (DLL3-targeting ADC): Advance three registration-enabling studies across 2L+ SCLC, 1L SCLC, and other neuroendocrine carcinomas (NECs) by the end of 2026. Three data readouts expected in 2026, including: – 2L+ SCLC: Updated global Phase 1 data highlighting intracranial response in patients with brain metastases. – 1L SCLC: Data from an ongoing Phase 1 combination study evaluating doublet and triplet regimens with a PD-L1 inhibitor, with or without chemotherapy; initiation of global Phase 1 study with novel combination. – Extrapulmonary NECs: Data from the Phase 1b portion of the ongoing global Phase 1b/2 study. ZL-1503 (IL-13/IL-31Rα bispecific antibody): First-in-Human (FIH) data from the ongoing global Phase 1/1b study expected in the second half of 2026, paving the way for Phase 2 development in atopic dermatitis (AD). ZL-6201 (LRRC15-targeting ADC): Global Phase 1 ongoing. ZL-1222 (PD-1/IL-12 immunocytokine): Investigational New Drug (IND)-enabling studies expected to be completed in 2026. ZL-1311 (T-cell engager (TCE) targeting MUC17): IND submission expected by year end. Zai Lab is building capabilities in TCEs and exploring additional immunocytokines beyond IL-12, with further details to be provided throughout the year. Commercial Execution and Key Near-Term Regional Launches to Drive Steady Growth VYVGART and VYVGART Hytrulo: Continue to increase patient utilization and duration of treatment in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). KarXT: Planned commercial launch in the first half of 2026, supported by a targeted commercial strategy, physician education, real-world evidence generation, and preparation for potential NRDL inclusion in 2027. Povetacicept and elegrobart: Both have pivotal readouts in 2026 and are expected to further strengthen regional revenue growth in the near term. Key Corporate Updates Below are key corporate updates since our last earnings release: Business Development: – We obtained the exclusive worldwide rights to develop and commercialize ZL‑1311, a next‑generation TCE targeting MUC17, which is a promising and druggable antigen overexpressed in up to ~50% of gastric and gastroesophageal junction cancers. This program represents Zai Lab’s first globally owned TCE and strategically expands our immuno‑oncology portfolio while leveraging our established expertise in GI cancers. ZL‑1311 is expected to enter global clinical development this year. – We formed a strategic collaboration with SciClone Pharmaceuticals (SciClone) for AUGTYRO™ (repotrectinib), which was approved in mainland China for ROS1‑positive non‑small‑cell lung cancer in May 2024 and for NTRK‑positive solid tumors in January 2026. Through this collaboration, Zai Lab will leverage SciClone’s commercialization infrastructure to broaden access and accelerate the commercial rollout of this innovative therapy for patients in need across mainland China. NRDL Updates: In December 2025, Zai Lab announced the successful renewals of VYVGART (efgartigimod alfa injection) for gMG patients who are anti-acetylcholine receptor (AChR) antibody positive, NUZYRA (omadacycline) for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) and ZEJULA (niraparib) for platinum-sensitive, first-line and recurrent ovarian cancer patients in China’s NRDL. Recent Pipeline Highlights Below are key product candidate updates since our last earnings release: Oncology Pipeline Zocilurtatug Pelitecan (zoci, DLL3 ADC): – Second-Line+ ES-SCLC: The global Phase 3 study evaluating the efficacy and safety of zoci versus investigator’s choice therapy (topotecan, lurbinectedin, or amrubicin) in patients with relapsed SCLC is ongoing. This pivotal study plans to enroll approximately 480 patients in 2L SCLC or 3L post‑tarlatamab SCLC, with the majority of enrollment anticipated to be completed this year. – Extrapulmonary NECs : In January 2026, Zai Lab dosed the first patient in the global Phase 2 portion of its ongoing Phase 1b/2 study in NECs. Zai Lab plans to present an initial data readout from the Phase 1b portion in the first half of 2026, complete enrollment for the Phase 2 portion, and advance the program into the registrational stage within the year. ZL-6201 (LRRC15 ADC): In January 2026, the FDA cleared the IND application for a global Phase 1 study in patients with sarcoma and potentially other LRRC15-positive solid tumors. The global Phase 1 study has been initiated. Tumor Treating Fields (TTFields): In February 2026, the FDA approved Optune Pax ® for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel. It is the first treatment approved by the FDA for locally advanced pancreatic cancer in nearly 30 years. China’s NMPA granted Innovative Medical Device Designation for the treatment of pancreatic cancer in August 2025. AUGTYRO™ (repotrectinib, ROS1/TRK): In December 2025, China’s NMPA approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib) for the treatment of adult patients with solid tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. Immunology, Neuroscience, and Infectious Disease Pipeline ZL-1503 (IL-13/IL-31Rα): In December 2025, Zai Lab dosed the first participant in a global Phase 1/1b study evaluating the safety, tolerability, pharmacokinetics, and efficacy of ZL-1503 for the treatment of AD. Zai Lab expects to report the first-in-human data from the global Phase 1 portion in the second half of 2026. VYVGART (FcRn): – Ocular myasthenia gravis (oMG): Zai Lab partner argenx announced in February 2026 that the Phase 3 ADAPT OCULUS met its primary endpoint (p-value=0.012), demonstrating that patients living with oMG and treated with VYVGART demonstrated statistically significant improvement from baseline in Myasthenia Impairment Index (MGII) Patient Reported Outcome (PRO) ocular scores at Week 4 compared to placebo. In the overall population, mean change from baseline in patients treated with VYVGART was a 4.04 point improvement in MGII PRO versus a mean change of 1.99 MGII PRO score in patients treated with placebo. VYVGART was well tolerated and had a favorable safety pro patients with oMG, consistent with prior studies. Zai Lab participated in the study in Greater China (mainland China, Hong Kong, Macau, and Taiwan, collectively). – Seronegative generalized myasthenia gravis (sn-gMG): In January 2026, the FDA accepted for Priority Review a supplemental Biologics License Application (sBLA) for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) sn-gMG, with a Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026. Zai Lab participated in the Phase 3 ADAPT SERON study in Greater China. KarXT (xanomeline and trospium chloride) (M1/M4-agonist): In December 2025, China’s NMPA approved the NDA for KarXT for the treatment of schizophrenia in adults. KarXT is the first schizophrenia therapy with a novel mechanism of action approved in more than 70 years, offering a fundamentally new approach to treating schizophrenia. The commercial launch in China is planned for the second quarter of 2026. Povetacicept (APRIL/BAFF): In December 2025, Zai Lab joined the global pivotal Phase 2/3 OLYMPUS study in primary membranous nephropathy (pMN) and dosed the first patient in mainland China. The FDA granted Fast Track and Orphan Drug designations for povetacicept in pMN, and the EMA has granted Priority Medicines (PRIME) designation. Elegrobart (anti-IGF-1R, subcutaneous): In December 2025, Zai Lab dosed the first patient in a registrational study in thyroid eye disease (TED) in mainland China. Partner Viridian plans to report topline results from two global registrational studies in patients with active TED and chronic TED in the first half of 2026. Anticipated Major Milestones in 2026 Expected Clinical Developments and Data Readouts Global Pipeline Zocilurtatug Pelitecan (zoci, DLL3 ADC) (formerly ZL-1310) Second-Line+ ES-SCLC: Zai Lab to present updated data on intracranial activity from the ongoing Phase 1 study in the first half of 2026. First-Line ES-SCLC: Zai Lab to provide data readout from the Phase 1 study evaluating zoci combination therapy (with atezolizumab and/or chemotherapy) in the second half of 2026 and advance zoci into a registrational study in 2026 based on emerging data. Zai Lab also plans to initiate a Phase 1 study to explore zoci in a novel combination in the first half of 2026. Extrapulmonary NECs: Zai Lab to provide data readout from the global Phase 1b portion of the ongoing Phase 1b/2 study evaluating zoci in patients with selected solid tumors in the first half of 2026 and advance into registrational development in 2026. ZL-1503 (IL-13/IL-31Rα) Zai Lab to provide the first-in-human data readout from the global Phase 1/1b study in 2026. Regional Pipeline Upcoming Potential NMPA Approvals Tisotumab Vedotin (Tissue Factor ADC) in recurrent or metastatic cervical cancer following progression on or after chemotherapy Tumor Treating Fields (TTFields) in locally advanced pancreatic cancer Efgartigimod (FcRn) Myositis: Zai Lab partner argenx to provide topline results from the global Phase 2/3 ALKIVIA study evaluating autoimmune inflammatory myopathies (AIM or myositis) in the third quarter of 2026. Zai Lab participated in the study in Greater China. Povetacicept (APRIL/BAFF) IgA Nephropathy (IgAN) : Zai Lab partner Vertex remains on track to release interim analysis data of the global Phase 3 RAINIER study in the first half of 2026 and also complete the submission in the first half of 2026, if data from the interim analysis are supportive. The FDA has granted Breakthrough Therapy Designation for this indication. pMN: Zai Lab and partner Vertex plan to complete the Phase 2 portion of the global pivotal Phase 2/3 OLYMPUS study and initiate the Phase 3 portion in mid-2026. Elegrobart (anti-IGF-1R, subcutaneous) Viridian to provide topline results from the global registrational REVEAL-1 study in active TED patients in the first quarter of 2026 and global registrational REVEAL-2 study in chronic TED in the second quarter of 2026. Zai Lab, through its license agreement with Zenas, obtained a sublicense to the Viridian anti-IGF-1R antibody and is proceeding with clinical development. Conference Call and Webcast Information Zai Lab will host a live conference call and webcast today, February 26, 2026, at 8:00 a.m. ET (9:00 p.m. HKT). Listeners may access the live webcast by visiting the Company’s website at . Participants must register in advance of the conference call. Details are as follows: Registration link for webcast (preferred): Registration link for dial-in: All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering. A replay will be available shortly after the call and can be accessed by visiting the Company’s website. About Zai Lab Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health worldwide. For additional information about Zai Lab, please visit or follow us at . Non-GAAP Measures In addition to results presented in accordance with GAAP, we disclose growth rates that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars. We have also presented a measure of adjusted loss from operations that adjusts GAAP loss from operations to exclude the impact of certain non-cash expenses including depreciation, amortization, and share-based compensation, which we refer to as “profitability.” These adjusted growth rates and adjusted loss from operations are non-GAAP measures. We believe that these non-GAAP measures are important for an understanding of the performance of our business operations and financial results and provide investors with an additional perspective on operational trends and greater transparency into our historical and projected operating performance. Although we believe the non-GAAP financial measures enhance investors’ understanding of our business and performance, these non-GAAP financial measures should not be considered an exclusive alternative to accompanying GAAP financial measures. Zai Lab Forward-Looking Statements This press release contains certain forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; our goals, objectives, and priorities and our expectations under our growth strategy (including our expectations regarding our commercial products and launches, clinical stage products, revenue growth, profitability, and cash flow); clinical development programs and related clinical trials; clinical trial data, data readouts, and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration partners; the anticipated benefits and potential of investments, collaborations, and business development activities; our profitability and timeline to profitability; our future financial and operating results; and financial guidance, including with respect to our capital allocation and investment strategy and our expected path to profitability. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “poised,” “positioned,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to obtain funding for our operations and business initiatives; (3) the results of our clinical and pre-clinical development of our product candidates; (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates; (5) risks related to doing business in China; and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U. Contacts For more information, please contact: Investor Relations: Christine Chiou / Cyan Liu +1 (917) 886-6929 / +86 195 3130 8895 christine.chiou1@zailaboratory.com / cyan.liu@zailaboratory.com Media: Shaun Maccoun / Xiaoyu Chen +1 (415) 317-7255 / +86 185 0015 5011 shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com Read full story here

Phase 1Phase 3License out/inDrug ApprovalBreakthrough Therapy

100 Deals associated with Omadacycline Tosylate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Omadacycline Tosylate	J01AA15	DB12455

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Community-acquired bacterial pneumonia	United States	Paratek Pharmaceuticals, Inc.	02 Oct 2018
Skin and skin structure infections	United States	Paratek Pharmaceuticals, Inc.	02 Oct 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cellulitis	Phase 3	China	Zai Lab (Shanghai) Co., Ltd.	01 Mar 2019
Cellulitis	Phase 3	China	Hangzhou Ausia Biological Technology Co. Ltd.	01 Mar 2019
Erysipelas	Phase 3	China	Zai Lab (Shanghai) Co., Ltd.	01 Mar 2019
Erysipelas	Phase 3	China	Hangzhou Ausia Biological Technology Co. Ltd.	01 Mar 2019
Community Acquired Pneumonia	Phase 3	Georgia	Paratek Pharmaceuticals, Inc.	22 Nov 2015
Non-complicated skin and skin structure infection	Phase 3	-	Paratek Pharmaceuticals, Inc.	01 Jul 2009
Skin structures and soft tissue infections	Phase 3	-	Paratek Pharmaceuticals, Inc.	01 Jul 2009
Complicated skin and skin structure infection	Phase 3	United States	Paratek Pharmaceuticals, Inc.	04 Apr 2009
Complicated skin and skin structure infection	Phase 3	United States	Novartis Pharmaceuticals Corp.	04 Apr 2009
Skin Diseases, Infectious	Phase 3	United States	Paratek Pharmaceuticals, Inc.	04 Apr 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05217537 (CTgov)	Phase 1	Bacterial Infections	23	Omadacycline (Adolescents, Cohort 1: 100 mg IV Omadacycline)	nrkrnznqmb(uprgftntay) = aecbwkbavg gyagdwsobu (ogrmjjoywy, 27.3) View more	-	09 Mar 2026
				Omadacycline (Children, Cohort 2: 100 mg IV Omadacycline)	nrkrnznqmb(uprgftntay) = qljmsujzks gyagdwsobu (ogrmjjoywy, 40.1) View more
NCT04922554 (Phase 2, CTgov)	Phase 2	Mycobacterium Abscessus Infection	66	Omadacycline (Omadacycline 300 mg)	ewfnoziqnh = lpcwfjbnte hjhslmifqk (nbqfkgyhdk, hjiokxuiae - ulnrvcdlys) View more	-	30 Jul 2025
				placebo (Placebo)	ewfnoziqnh = bglbvsbiov hjhslmifqk (nbqfkgyhdk, zxudkzlxol - imcibwlykl) View more
NCT04922554 (Phase 2, ATS2025)	Phase 2	Mycobacterium Abscessus Infection	-	Omadacycline 300mg	vvxqeqdmmd(hctrtnezbv) = tbljetzosn dwiglleptj (qalutsgjyr )	Positive	16 May 2025
				Placebo	vvxqeqdmmd(hctrtnezbv) = qmqaqzuiac dwiglleptj (qalutsgjyr )
NCT04779242 (CTgov)	Phase 3	Community-acquired bacterial pneumonia	670	Omadacycline (Omadacycline)	mjdepdtydj = istevlxwdd rezbtvwyec (vmlpbkwmoh, rydtmcdhvr - vmoksebfel) View more	-	09 Apr 2025
				Moxifloxacin (Moxifloxacin)	mjdepdtydj = yktcmsvnui rezbtvwyec (vmlpbkwmoh, ybyzwoztxj - yhnxzulbnw) View more
NCT05515562 (CTgov)	Phase 4	-	8	Omadacycline Injection	ggvvbxngkl(xjgparphin) = zosseepyie lrkoszpyuu (kifmucnqix, 0.0622) View more	-	17 Mar 2025
NCT04460586 (Pubmed \| Clin Pharmacokinet)	Phase 4	Cystic Fibrosis	9	Omadacycline 100 mg IV	ektesojjej(rfweisifjs) = aafoevnhtm uhlnvxpphk (rtywdgxllr )	Positive	01 Dec 2024
				Omadacycline 300 mg oral	ektesojjej(rfweisifjs) = iezacuwpwk uhlnvxpphk (rtywdgxllr )
NCT04922554 (GlobeNewswire) Manual	Phase 2	Mycobacterium Infections, Nontuberculous	66	omadacycline	tamdespydh(yaxmszpstr) = ugevpmfofd wservhjogh (mgccvpqbnx ) View more	Positive	08 Nov 2024
				Placebo	tamdespydh(yaxmszpstr) = avvqtngvfb wservhjogh (mgccvpqbnx ) View more
NCT02378480 \| NCT02877927 (OASIS-1;OASIS-2, Pubmed \| Infect Dis Ther) Manual	Phase 3	Skin Diseases, Bacterial	-	Intravenous Omadacyclinelinezolid	iredjewkse(hxosfbvala) = omfkvbdhuv hlzgkpquoc (aagoyzordy ) View more	Positive	26 Oct 2024
				Oral Omadacyclinelinezolid	iredjewkse(hxosfbvala) = sibbhdudae hlzgkpquoc (aagoyzordy ) View more
GlobeNewswire Manual	Approved	Community-acquired bacterial pneumonia	670	NUZYRA® (omadacycline)	zplvjmhhtr(ydkkenumxd) = towdhnyzjk jzzyfbautd (ljxstoesrj ) Met View more	Positive	18 Jul 2024
				Moxifloxacin	zplvjmhhtr(ydkkenumxd) = dwrrnmspbf jzzyfbautd (ljxstoesrj ) Met View more
75A50120C00001 (GlobeNewswire) Manual	Not Applicable	Inhalation Anthrax	-	NUZYRA	brsqukmoxe(zxfxljwscn) = kygyeatnqa meogvasktr (vclahdtwdn ) View more	Positive	05 Mar 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis